Ensign Peak Advisors, Inc Essa Pharma Inc. Transaction History

Ensign Peak Advisors, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$3.15 - $7.94 $198,972 - $501,538	-63,166 Reduced 70.62%	26,282 $83,000
Q4 2021 Feb 11, 2022	BUY	$7.8 - $14.38 $49,764 - $91,744	6,380 Added 7.68%	89,448 $1.27 Million
Q3 2021 Nov 12, 2021	SELL	$7.76 - $29.37 $737,200 - $2.79 Million	-95,000 Reduced 53.35%	83,068 $665,000
Q2 2021 Aug 13, 2021	BUY	$24.17 - $34.28 $470,348 - $667,088	19,460 Added 12.27%	178,068 $5.09 Million
Q1 2021 May 12, 2021	BUY	$11.61 - $32.08 $1.28 Million - $3.54 Million	110,442 Added 229.29%	158,608 $4.61 Million
Q4 2020 Feb 12, 2021	BUY	$5.47 - $12.1 $101,572 - $224,684	18,569 Added 62.74%	48,166 $575,000
Q3 2020 Nov 12, 2020	BUY	$6.0 - $7.79 $177,582 - $230,560	29,597 New	29,597 $204,000

35.1M

15.8K

21K

Ticker EPIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,073,100
Market Cap $75.4M
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreem...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.